Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Convention Name November 6, 2024 4:30 PM ET
Firm Contributors
Ryan Asay – Senior Vice President-Company Affairs
Mark Goldsmith – Chairman and Chief Government Officer
Steve Kelsey – President-Analysis and Growth
Jack Anders – Chief Monetary Officer
Wei Lin – Chief Medical Officer
Convention Name Contributors
Peter Lawson – Barclays
Michael Schmidt – Guggenheim Securities
Jay Olson – Oppenheimer
Marc Frahm – TD Cowen
Alec Stranahan – Financial institution of America
Jonathan Chang – Leerink Companions
Eric Joseph – J.P. Morgan
Laura Prendergast – Raymond James
Operator
Good day and thanks for standing by. Welcome to Revolution Medication’s Q3 2024 Earnings Convention Name. At the moment, all members are in a listen-only mode. After the speaker’s presentation, there shall be a question-and-answer session. [Operator Instructions] Please be suggested that as we speak’s convention is being recorded.
I’d now like at hand the convention over to your first speaker as we speak, Ryan Asay, Senior Vice President of Company Affairs. Please go forward.
Ryan Asay
Thanks, and welcome, everybody, to the third quarter 2024 earnings name. Becoming a member of me on as we speak’s name are Dr. Mark Goldsmith, Revolution Medication’s Chairman and Chief Government Officer; Dr. Steve Kelsey, our President of R&D; and Jack Anders, our Chief Monetary Officer. Dr. Wei Lin, our Chief Medical Officer, will be part of us for the Q&A portion of as we speak’s name.
I wish to inform you that sure statements we make throughout this name shall be forward-looking as a result of such statements take care of future occasions and are topic to many dangers and uncertainties. Precise outcomes might differ materially from these within the forward-looking statements. For a full dialogue of those dangers and uncertainties, please evaluate our annual report on Type 10-Okay and our quarterly report on Type 10-Q which might be filed with the U.S. Securities and Alternate Fee. This
